// App-Quantinova.ai

P1027 : RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES

Researchers

Presenter

  • Tracy George

Principal Investigators

  • Kristin H. Karner

  • Karen A. Moser

  • Anton Rets

  • Andreas Reiter

  • Deepti H. Radia

  • Michael Deininger

  • Hui-Min Lin

  • Daniel J. DeAngelo

Medical Centers

  • St Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Blueprint Medicines,Cambridge,United States

  • Blueprint Medicines Corporation,Zug,Schwe

  • Medical Oncology,Dana-Farber Cancer Institute,Boston,Vereinigte Staaten

  • Department of Pathology,ARUP Laboratories, University of Utah, School of Medicine,Salt Lake City,Stati Uniti

  • Department of Hematology and Oncology,University Hospital Mannheim, Heid

  • Blueprint Medicines Corporation,Zug,Швейцария

  • Blueprint Medicines Corporation,Cambridge,États-unis

  • Department of Pathology,ARUP Laboratories, University of Utah, School of Medicine,Salt Lake City,Stati Uniti

  • Versiti Blood Research Institute,Milwaukee,Estados Unidos

  • Department of Pathology,ARUP Laboratories, University of Utah, Scho

  • Versiti, Blood Research Institute, Milwaukee, United States

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Blueprint Medicines Corporation,Zug,Schwe

  • Versiti Blood Research Institute,Milwaukee,Estados Unidos

  • Department of Pathology,ARUP Laboratories, University of Utah, School of Medicine,Salt Lake City,Stati Uniti

  • Versiti, Blood Research Institute, Milwaukee, United States

  • Blueprint Medicines Corporation,Zug,Schwe

  • Blueprint Medicines Corporation,Zug,Schwe

  • Versiti Blood Research Institute,Milwaukee,Estados Unidos

  • Versiti, Blood Research Institute, Milwaukee, United States

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Blueprint Medicines Corporation,Zug,Schwe

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Blueprint Medicines Corporation,Zug,Schwe

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Blueprint Medicines,Cambridge,United States

  • Department of Hematology and Oncology,University Hospital Mannheim, Heidelberg University,Mannheim,Deutschland

  • St Thomas' NHS Foundation Trust,Lon

  • Blu

  • Blueprint Medicines Corporation,Cambridge,États-unis

  • Blueprint Medicines Corporation, Cambridge, MA

  • Department of Hematology and Oncology,University Hospital Mannheim, Heidelberg University,Mannheim,Deutschland

  • Versiti Blood Research Institute,Milwaukee,Estados Unidos

  • Department of Radiation Oncology, Dana-Farber Cancer Institute Boston MA United States

  • Department of Hematology and Oncology,University Hospital Mannheim, Heidelberg University,Mannheim,Deutschland

  • Blueprint Medicines Corporation,Zug,Schwe

  • Blueprint Medicines,Cambridge,United States

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • Blueprint Medicines Corporation,Zug,Schwe

  • Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital,London,Royaume-uni

  • Guy's &amp

Locations

  • United States

  • Germany

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Mastocytosis

Biomarkers

  • Interleukin 2 Receptor Subunit Alpha

  • Cluster of Differentiation 30

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved